Abstracts Archive - Page 732 of 2425 - ACR Meeting Abstracts

Abstract Number: 1572 • ACR Convergence 2020
Clinical Characteristics of Methotrexate Associated Lymphoproliferative Disorders and RA Treatment After Lymphoproliferative Onset in 92 Cases
Tomohiro Kameda¹, Shusaku Nakashima¹, Masayuki Inoo², Ikuko Onishi², Noriyuki Kurata², Risa Wakiya³, Mai Mahmound Fahmy Mansour¹, Koichi Sugihara¹, Yusuke Ushio¹, Mikiya Kato¹, Hiromi Shimada¹ and Hiroaki Dobashi¹, ¹Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kita-gun, Kagawa, Japan, ²Internal Medicine, Utazu hospital, Ayauta-gun, Kagawa, Japan, ³Department of Internal Medicine, Division of Haematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University., Kagawa, Kagawa, Japan
Background/Purpose: Lymphoproliferative disorders (LPD) that develop in rheumatoid arthritis (RA) patients treated with MTX (MTX-LPD) is one of the important complications for RA patients. MTX-LPD…
Abstract Number: 1571 • ACR Convergence 2020
Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy
Sang Kim¹, Jean Tayar², Maria Suarez-Almazor³, Huifang Lu⁴, Yang-Zhi Zhao⁵, Margarita Divenko⁵, William Padron⁵, Emma Rodriguez⁵, Sattva Neelapu⁵, Jennifer Wang⁵, Amish Shah⁵, Nizar Tannir⁵, Don Gibbons⁵, Guillermo Garcia-Manero⁵, Hussein Tawbi⁵, Patrick Hwu⁵, Andrew Futreal⁵, Adi Diab⁵ and Roza Nurieva⁵, ¹The Univesrity of Texas MD Andesron Cancer Center, Pearland, TX, ²The University of Texas, MD Anderson Cancer Center, Houston, TX, ³University of Texas MD Anderson Cancer Center, Houston, TX, ⁴MD Anderson, Houston, TX, ⁵MD Anderson, Houston
Background/Purpose: Despite of unprecedented clinical success in cancer therapeutics, immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Arthritis-irAE can…
Abstract Number: 1577 • ACR Convergence 2020
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis
Jeffrey Sarazin¹, Ann Impens², Nada Abdulaziz¹, Stacey Anderson³, Leslie Fecher¹, Christopher Lao¹ and Elena Schiopu¹, ¹Michigan Medicine, Ann Arbor, MI, ²Midwestern University, Ann Arbor, IL, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related…
Abstract Number: 1579 • ACR Convergence 2020
Assessing the Effect of Calcineurin Inhibitors for Immune-related Adverse Event Management on Tumor Response
Pankti Reid¹, Daniel Olson² and Thomas Gajewski², ¹University of Chicago, Chicago, IL, ²University of Chicago Medical Center, Department of Medicine, Section of Hematology Oncology, Chicago
Background/Purpose: High grade immune-related adverse events (irAEs) to cancer immune checkpoint inhibitors (ICI) require considerable immunosuppression (IS) with high-dose steroids and steroid-sparing IS (SSIS) for…
Abstract Number: 1574 • ACR Convergence 2020
Over Half of Patients with Immune Checkpoint Inhibitor-related Myositis, Myasthenia Gravis and/or Myocarditis Have Autoantibodies: Results from a Systematic Literature Review
Nilasha Ghosh¹, Karmela Kim Chan², Bridget Jivanelli³ and Anne Bass¹, ¹Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ²Hospital For Special Surgery, New York, NY, ³Hospital for Special Surgery, New York
Background/Purpose: Although immune checkpoint inhibitor (ICI) cancer treatments are known to activate cytotoxic T-cells, autoantibodies may also contribute to the development of immune-related adverse events…
Abstract Number: 1569 • ACR Convergence 2020
Immune Related Adverse Events Related to Check Point Inhibitors Among Outpatients in an Academic Center
Bushra Akram¹, Aleena Itani¹, Mohammad Razaq², Samera Vaseer¹, Sara Vesely¹ and Pawan Acharya¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Immune check point inhibitors (ICIs) allow the body to recognize tumor cells as non-self, resulting in immune-cell mediated tumor cell destruction. These therapies have the…
Abstract Number: 1582 • ACR Convergence 2020
Average Follow-up Time After Telemedicine Visit Is Longer Than Conventional Face-to-Face Visit in Outpatient Rheumatology Practice During COVID-19 Pandemic
Deepan Dalal¹, Tzu-Chun Chu², Brad Crough³, Janine Molino², David Hemendinger⁴ and Bharat Ramratnam², ¹Brown University, East Providence, RI, ²Brown University, Providence, RI, ³Brown Physicians Incorporation, East Providence, RI, ⁴Brown Physicians Incorporation, Providence, RI
Background/Purpose: In the era of recent COVID-19 crisis, outpatient rheumatology practices resorted to telemedicine to deliver longitudinal care, a fundamental component of chronic disease management. …
Abstract Number: 1585 • ACR Convergence 2020
Lessons Learned Through Rapid Quality Improvement for Telehealth Implementation in an Academic Rheumatology Practice During the COVID-19 Pandemic
Julie Thomas¹, Dorota Lebiedz-Odrobina¹, Kyle Register¹, Francesca Ferrara¹, Danielle Barlow¹, Alicia Riddle¹ and Karla Miller², ¹University of Utah, Salt Lake City, UT, ²Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT
Background/Purpose: The COVID-19 pandemic created an urgent need for access to care while preserving patient safety through social distancing. Prior to the pandemic, patients were…
Abstract Number: 1586 • ACR Convergence 2020
Rheum Service: Comprehensive Virtual Care During COVID-19
Stephanie Gottheil¹ and Joseph Carson¹, ¹London Rheumatology, London, ON, Canada
Background/Purpose: During COVID-19, patients require timely access to rheumatologists while adhering to physical distancing guidelines. In this quality improvement project, we developed a comprehensive virtual…
Abstract Number: 1581 • ACR Convergence 2020
Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review
Michael Cunningham¹, Carolina Alvarez², Shruti Saxena Beem³, Todd Schwartz⁴ and Rumey Ishizawar⁵, ¹UNC Hospitals, Durham, NC, ²University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Miami, FL, ³University of North Carolina at Chapel Hill, Chapel Hill, ⁴University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁵University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Immune checkpoint inhibitors (ICIs) target checkpoint proteins PD-1/PD-L1 and CTLA-4 to activate and enhance the cytotoxic effects of T lymphocytes against tumor cells [1-2].…
Abstract Number: 1592 • ACR Convergence 2020
Improving Documentation of Smoking Cessation Counseling Among Spondyloarthropathy Smokers
Yusuf Chao¹, Jake Hutto², Elena Joerns², Rashmi Arora³, Una Makris¹ and Swathi Reddy³, ¹UT Southwestern Medical Center, Dallas, TX, ²Division of Rheumatic Diseases, UT Southwestern Medical Center, Dallas, TX, ³Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Smoking is prevalent among patients with spondyloarthropathies (SpA) and is associated with higher disease activity, poorer quality of life, and dampened response to biologic…
Abstract Number: 1589 • ACR Convergence 2020
An Initiative to Improve Timely Glucocorticoid Tapering in Vasculitis
Arielle Mendel¹, Daniel Ennis², Shirley Lake³, Simon Carette⁴ and Christian Pagnoux⁵, ¹Division of Rheumatology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada, ³Division of Rheumatology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, ⁴Division of Rheumatology, Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, ON, Canada, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Vasculitis guidelines recommend scheduled glucocorticoid (GC) tapering to avoid toxicity. In an audit of 130 consecutive new patients on GC assessed in our tertiary…
Abstract Number: 1584 • ACR Convergence 2020
Telemedicine Visits During COVID-19 Improved Clinic Show Rates
Reem Alkilany¹ and Raymond Hong², ¹MetroHealth medical center, lakewood, OH, ²Metrohealth Medical center, Richfield, OH
Background/Purpose: The COVID-19 pandemic has tremendously affected the healthcare sector. State of Ohio officials recommended to hold in-person outpatient visits and elective procedures to limit…
Abstract Number: 1476 • ACR Convergence 2020
Trends in Mortality and Cause-specific Mortality Among Patients with Psoriasis and Psoriatic Arthritis in Ontario, Canada
Keith Colaco¹, Jessica Widdifield², Jin Luo³, Cheryl Rosen⁴, Raed Alhusayen⁵, J. Michael Paterson⁶, Willemina Campbell⁷, Karen Tu⁴, Sasha Bernatsky⁸, Dafna Gladman⁹ and Lihi Eder¹⁰, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³ICES, Toronto, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada, ⁶ICES, University of Toronto, Toronto, ON, Canada, ⁷University Health Network, University of Toronto, Toronto, ON, Canada, ⁸The Research Institute of the McGill University Health Centre, Montreal, ON, Canada, ⁹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ¹⁰Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Several studies have consistently demonstrated that psoriasis is associated with an increased risk of mortality compared to the general population. However, the excess risk…
Abstract Number: 1351 • ACR Convergence 2020
Efficacy of Ixekizumab versus Adalimumab in Psoriatic Arthritis (PsA) Patients with and Without Moderate-to-severe Psoriasis: 52-week Results from a Multicentre, Randomised Open-label Study
Lars Erik Kristensen¹, Masato Okada², William Tillett³, Soyi Liu-Leage⁴, Celine El Baou⁵, Andrew Bradley⁵, Gabriella Meszaros⁴ and Kurt de Vlam⁶, ¹The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, ²St. Luke's International University, Tokyo, Japan, Chuo-ku, Tokyo, Japan, ³Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, ⁶Department of Rheumatology, University of Leuven, Belgium, Leuven, Belgium
Background/Purpose: Ixekizumab (IXE), a selective interleukin-17A antagonist, is approved for the treatment of active PsA, moderate-to-severe psoriasis (PsO), and radiographic/non-radiographic axial SpA in adults. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].